According to the World Health Organization, pharmacovigilance is defined as:
“…the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem.” Essentially, it is drug safety. Pharmacovigilance ensures the rigorous testing of clinical drugs to improve patient care and reduce the risk of negative side effects. Present throughout the drug lifecycle, PV certifies whether a drug works and if it is safe to use.
A serious adverse event is a reaction that causes life-threatening harm to the individual, resulting in hospitalisation, significant disability or incapacitation, congenital abnormality, or at worst, death. Anything that requires intervention to prevent these is also classified as serious. In any case, adverse event reporting is compulsory and critical to the success of PV.
Saudi Food and Drug Authority-Drug sector
Email: Npc.drug@sfda.gov.sa
Online: http://ade.sfda.gov.sa
Call NPC at +966-1-2759222
Ext : 2317 -2356- 2353-2354- 2334-2340
Fax:+966-1-2057662
Mail:
National Parmacovigilance Center (NPC)
Saudi Food and Drug Authority-Drug sector
3292 Northern Ring Road
ALNafal district
Riyadh 13312 – 2688
Kingdom of Saudi Arabia
• Tel: +966-11- 205 5636
• Email: info@avicenna-ihs.com
• Mob. +966-50-9009 270
• Email: ehab@avicenna-ihs.com
• Email: hiba@avicenna-ihs.com
Or:
In case of experiencing any side effect while using any of Avicenna IHS medications please fill our ADR Report.
Please download the our ADR report here